Faculty Profile

Samir Undevia
Section of Hematology / Oncology
Clinical Associate of Medicine
Referring Physician Access Line: 1-877-DOM-2730

Academic Interests

Dr. Undevia is involved in clinical research in the areas of genitourinary oncology ( kidney, bladder and prostate), bone and soft tissue sarcoma, and new drug development.

Clinical Interests

Genitourinary cancers (kidney, bladder, prostate, testis); bone and soft tissue sarcomas; investigational drug therapy


  • Undevia SD, Vogelzang NJ, Mauer AM, Janisch L, Mani S, Ratain MJ. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest. New Drugs 22 449-58 (2004).
  • Innocenti F, Undevia SD, Iyer L, Das S, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ: Genetic variants in the UDP-Glucuronosyl Transferase 1A1 gene predict the risk of severe neutropenia of irinotecan in cancer patients. J. Clin Oncol. 15 1382-8 (2004)
  • Undevia SD, Kindler HL, Janisch L, Olson SC, Schilsky RL, Vogelzang NJ, Kimmel KA, Macek TA, Ratain MJ. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann. Oncol.2004 Nov;15(11):1705-11
  • Innocenti F, Undevia SD, Ramirez J, Mani S, Schilsky RL, Vogelzang NJ, Prado M, Ratain MJ. A phase I trial of pharmacological modulation of irinotecan with cyclosporine A and phenobarbital. Clin. Pharmacol. Ther. 2004 Nov;76(5):490-502


  • BS, 1992, Cornell University, Electrical Engineering
  • MD, 1997, New York University, Medicine
  • Residency, 2000, The University of Chicago, Internal Medicine
  • Fellowship, 2004, The University of Chicago, Hematology Oncology